--- library_name: setfit tags: - setfit - sentence-transformers - text-classification - generated_from_setfit_trainer datasets: - CabraVC/vector_dataset_stratified_ttv_split_2023-12-05_21-07 metrics: - accuracy widget: - text: 'for the taliglucerase alfa NDA that set forth additional requirements for approval. Protalix will work with the FDA to determine next steps. In May 2010, the FDA issued a “complete response” letter requesting additional information in connection with our supplemental NDA seeking approval to use Sutent for the treatment of pancreatic neuroendocrine tumors. We have provided the requested information, including an analysis of independently reviewed scans, and are working with the FDA to pursue regulatory approval. In April 2010, we received a “complete response” letter from the FDA for the Genotropin Mark VII multidose disposable device submission. In August 2010, we submitted our response to address the requests and recommendations included in the FDA letter. In June 2010, we received a “complete response” letter from the FDA for the Celebrex chronic pain supplemental NDA. We are working with the FDA to determine the next steps. In October 2009, we received a “complete response” letter from the FDA with respect to the supplemental NDA for Geodon for the treatment of acute bipolar mania in children and adolescents aged 10 to 17 years. In October 2010, we submitted our response to address the issues raised in the FDA letter. In April 2010, we received a “warning letter” from the FDA with respect to the clinical trial in support of this supplemental NDA. We are working with the FDA to address the issues raised in the letter. Boehringer Ingelheim (BI), our alliance partner, holds the NDAs for Spiriva Handihaler and Spiriva Respimat. In September 2008, BI received a “complete response” letter from the FDA for the Spiriva Respimat submission. The FDA is seeking additional data, and we are coordinating with BI, which is working with the FDA to provide the additional information. A full response will be submitted to the FDA upon the completion of planned and ongoing studies. In September 2007, we received an “approvable” letter from the FDA for Zmax that set forth requirements to obtain approval for the pediatric acute otitis media (AOM) indication based on pharmacokinetic data. A supplemental filing for pediatric AOM and sinusitis remains under review. Two “approvable” letters were received by Wyeth in April and December 2007 from the FDA for Viviant (bazedoxifene), for the prevention of post-menopausal osteoporosis, that set forth the additional requirements for approval. In May 2008, Wyeth received an “approvable” letter from the FDA for the treatment of post-menopausal osteoporosis. The FDA is seeking additional data, and we have been systematically working through these requirements and seeking to address the FDA’s concerns. In February 2008, the FDA advised Wyeth that it expects to convene an advisory committee to review the pending NDAs for both the treatment and prevention indications after we submit our response to the “approvable” letters. In April 2009, Wyeth received approval in the EU for CONBRIZA (the EU trade name for Viviant) for the treatment of post-menopausal osteoporosis in women at increased risk of fracture. Viviant was also approved in Japan in July 2010 for the treatment of post-menopausal osteoporosis. In July 2007,' - text: "year 2005, offset by a $663 million decline in Upgrade Advantage earned revenue.\ \ \n\nInformation Worker operating income increased in fiscal year 2006 primarily\ \ due to the revenue growth, partially offset by a $283 million or 15% increase\ \ in sales and marketing expenses related to supporting field sales efforts and\ \ a $71 million or 10% increase in research and development expenses. Headcount-related\ \ costs increased 14% during fiscal year 2006 reflecting both an 18% increase\ \ in headcount related to supporting field sales efforts and research and development\ \ investments in future products and an increase in salaries and benefits for\ \ existing headcount, partially offset by a decrease in stock-based compensation\ \ expense. Information Worker operating income growth for fiscal year 2005 was\ \ primarily due to the revenue growth and a $304 million decrease in stock-based\ \ compensation expense. Operating expenses were also impacted by a reduction in\ \ marketing campaign costs from the previous period associated with the launch\ \ of Office 2003. This decline was offset by an increase in headcount-related\ \ costs as a result of an increase in headcount and an increase in salaries and\ \ benefits for existing headcount. \n\n \n\nMicrosoft Business Solutions \n\n\  \n\nMicrosoft Business Solutions provides business management software solutions\ \ targeted to businesses of varying sizes. The main products consist of enterprise\ \ resource planning (“ERP”) solutions, customer relationship management (“CRM”)\ \ software, retail solutions, Microsoft Partner Program (“MSPP”), and related\ \ services. Microsoft Business Solutions also includes the Small\n\n\n\n\n\n \n\ \n \n\n \n\nand Mid-market Solutions and Partners (“SMS&P”), which focuses on\ \ sales to customers and partners in the small and mid-market customer segments.\ \ Revenue is derived from software and services sales, with software sales representing\ \ a significant amount of total revenue. Software revenues include both new software\ \ licenses and enhancement plans, which provide customers with future software\ \ upgrades over the period of the plan. Our solutions are delivered through a\ \ worldwide network of channel partners that provide services and local support.\ \ \n\nMicrosoft Business Solutions revenue increased in fiscal year 2006 driven\ \ by new users for Microsoft CRM and existing Dynamics ERP customers purchasing\ \ functionality and user licenses. The increase in Microsoft Business Solutions\ \ revenue in fiscal year 2005 was mainly due to 10% revenue growth in software\ \ partially offset by 25% decline in services revenue. The software revenue increase\ \ was driven by 9% growth in license revenue and 16% growth in enhancement revenue\ \ and was attributed to growth in ERP and CRM solutions and an increase in MSPP\ \ subscriptions. \n\nMicrosoft Business Solutions operating income increased in\ \ fiscal year 2006 reflecting the increase in revenue accompanied by a $56 million\ \ decrease in sales and marketing expense as a result of decreased net SMS&P spending. Headcount-related\ \ costs increased 3% reflecting both a 10% increase in headcount and an increase\ \ in salaries and benefits for existing headcount, partially offset by a decrease\ \ in stock-based compensation expense." - text: '2004 Management''s Discussion and Analysis of Financial Condition and Results of Operations This section and other parts of this Form 10-K contain forward-looking statements that involve risks and uncertainties. Forward-looking statements can also be identified by words such as "anticipates," "expects," "believes," "plans," "predicts," and similar terms. Forward-looking statements are not guarantees of future performance and the Company''s actual results may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such differences include, but are not limited to, those discussed in the subsection entitled "Factors That May Affect Future Results and Financial Condition" below. The following discussion should be read in conjunction with the consolidated financial statements and notes thereto included in Item 8 of this Form 10-K. All information presented herein is based on the Company''s fiscal calendar. The Company assumes no obligation to revise or update any forward-looking statements for any reason, except as required by law. Executive Overview Apple designs, manufactures and markets personal computers and related software, services, peripherals and networking solutions. The Company also designs, develops and markets a line of portable digital music players along with related accessories and services including the online distribution of third-party music and audio books. The Company''s products and services include the Macintosh line of desktop and notebook computers, the iPod digital music player, the Xserve server and Xserve RAID storage products, a portfolio of consumer and professional software applications, the Mac OS X operating system, the online iTunes Music Store, a portfolio of peripherals that support and enhance the Macintosh and iPod product lines, and a variety of other service and support offerings. The Company sells its products worldwide through its online stores, its own retail stores, its direct sales force, and third-party wholesalers, resellers and value added resellers. In addition, the Company sells a variety of third-party Macintosh compatible products, including computer printers and printing supplies, storage devices, computer memory, digital video and still cameras, personal digital assistants, and various other computing products and supplies through its online and retail stores. The Company sells to education, consumer, creative professional, business and government customers. A further description of the Company''s products may be found in Part I, Item 1 of this document under the heading "Business." The Company''s business strategy leverages its unique ability, through the design and development of its own operating system, hardware and many software applications and technologies, to bring to its customers around the world compelling new products and solutions with superior ease-of-use, seamless integration and innovative industrial design. The Company participates in several highly competitive markets, including personal computers with its Macintosh line of computers, consumer electronics with its iPod line of digital music players and distribution of' - text: 'we have access to significant distribution networks in rural and suburban areas in Brazil and the opportunity to register and commercialize Teuto’s products in various markets outside Brazil. For additional information, see also Notes to Consolidated Financial Statements—Note 2D. Acquisitions, Divestitures, Collaborative Arrangements and Equity-Method Investments: Equity-Method Investments. • On October 6, 2010, we completed our acquisition of FoldRx Pharmaceuticals, Inc. (FoldRx), a privately held drug discovery and clinical development company. FoldRx’s lead product candidate, Vyndaqel (tafamidis meglumine), was approved in the EU in November 2011 and our new drug application was accepted for review in the U.S. in February 2012. This product is a first-in-class oral therapy for the treatment of transthyretin familial amyloid polyneuropathy (TTR-FAP), a progressively fatal genetic neurodegenerative disease, for which liver transplant is the only treatment option currently available. Our acquisition of FoldRx has increased our presence in the growing rare medical disease market, which complements our Specialty Care unit. For additional information regarding Vyndaqel (tafamidis meglumine), see the “Product Developments—Biopharmaceutical” section of this Financial Review. The total consideration for the acquisition was approximately $400 million. For additional information about the acquisition, see Notes to Consolidated Financial Statements—Note 2A. Acquisitions, Divestitures, Collaborative Arrangements and Equity-Method Investments: Acquisitions. Our Financial Guidance for 2013 We forecast 2013 revenues of $56.2 billion to $58.2 billion, Reported diluted earnings per common share (EPS) of $1.50 to $1.65 and Adjusted diluted EPS of $2.20 to $2.30. The exchange rates assumed in connection with the 2013 financial guidance are as of mid-January 2013. For an understanding of Adjusted income and Adjusted diluted EPS (both non-GAAP financial measures), see the “Adjusted Income” section of this Financial Review. The 2013 financial guidance reflects the benefit of a full-year contribution from Zoetis. We plan to update this guidance in April 2013 to reflect the impact of the recent initial public offering (IPO) of an approximate 19.8% ownership interest in Zoetis. For additional information on the IPO, see Notes to Consolidated Financial Statements—Note 19A. Subsequent Events: Zoetis Debt Offering and Initial Public Offering. The following table provides a reconciliation of 2013 Adjusted income and Adjusted diluted EPS guidance to 2013 Reported net income attributable to Pfizer Inc. and Reported diluted EPS attributable to Pfizer Inc. common shareholders guidance: Our 2013 financial guidance is subject to a number of factors and uncertainties—as described in the “Forward-Looking Information and Factors That May Affect Future Results”, “Our Operating Environment” and “Our Strategy” sections of this Financial Review and in Part I, Item 1A, “Risk Factors”, of our 2012 Annual Report on Form 10-K. SIGNIFICANT ACCOUNTING POLICIES AND APPLICATION OF CRITICAL ACCOUNTING ESTIMATES For a description of our significant accounting policies, see Notes to' - text: "as a component of Other (income) expense, net; and \n\na $ 56 million decrease\ \ in foreign exchange losses related to the difference between actual foreign\ \ currency exchange rates and standard foreign currency exchange rates assigned\ \ to the NIKE Brand geographic operating segments and Converse, net of hedge gains;\ \ these losses are reported as a component of consolidated gross margin. \n\n\ Foreign Currency Exposures and Hedging Practices \n\nOverview \n\nAs a global\ \ company with significant operations outside the United States, in the normal\ \ course of business we are exposed to risk arising from changes in currency exchange\ \ rates. Our primary foreign currency exposures arise from the recording of transactions\ \ denominated in non-functional currencies and the translation of foreign currency\ \ denominated results of operations, financial position and cash flows into U.S.\ \ Dollars. \n\nOur foreign exchange risk management program is intended to lessen\ \ both the positive and negative effects of currency fluctuations on our consolidated\ \ results of operations, financial position and cash flows. We manage global foreign\ \ exchange risk centrally on a portfolio basis to address those risks that are\ \ material to NIKE, Inc. We manage these exposures by taking advantage of natural\ \ offsets and currency correlations that exist within the portfolio and, where\ \ practical and material, by hedging a portion of the remaining exposures using\ \ derivative instruments such as forward contracts and options. As described below,\ \ the implementation of the NIKE Trading Company (“NTC”) and our foreign currency\ \ adjustment program enhanced our ability to manage our foreign exchange risk\ \ by increasing the natural offsets and currency correlation benefits that exist\ \ within our portfolio of foreign exchange exposures. Our hedging policy is designed\ \ to partially or entirely offset the impact of exchange rate changes on the underlying\ \ net exposures being hedged. Where exposures are hedged, our program has the\ \ effect of delaying the impact of exchange rate movements on our Consolidated\ \ Financial Statements; the length of the delay is dependent upon hedge horizons.\ \ We do not hold or issue derivative instruments for trading or speculative purposes.\ \ \n\nTransactional Exposures \n\nWe conduct business in various currencies and\ \ have transactions which subject us to foreign currency risk. Our most significant\ \ transactional foreign currency exposures are: \n\n• Product Costs — NIKE’s product\ \ costs are exposed to fluctuations in foreign currencies in the following ways:\ \ \n\nProduct purchases denominated in currencies other than the functional currency\ \ of the transacting entity: \n\nCertain NIKE entities, including those supporting\ \ our North America, Greater China, Japan and European geographies, purchase product\ \ from the NTC, a wholly-owned sourcing hub that buys NIKE branded products from\ \ third-party factories, predominantly in U.S. Dollars. The NTC, whose functional\ \ currency is the U.S. Dollar, then sells the products to NIKE entities in their\ \ respective functional currencies. When the NTC sells to a NIKE entity with a\ \ different functional currency, the result is a foreign currency exposure for\ \ the NTC. \n\nOther" pipeline_tag: text-classification inference: true model-index: - name: SetFit results: - task: type: text-classification name: Text Classification dataset: name: CabraVC/vector_dataset_stratified_ttv_split_2023-12-05_21-07 type: CabraVC/vector_dataset_stratified_ttv_split_2023-12-05_21-07 split: test metrics: - type: accuracy value: 0.4583333333333333 name: Accuracy --- # SetFit This is a [SetFit](https://github.com/huggingface/setfit) model trained on the [CabraVC/vector_dataset_stratified_ttv_split_2023-12-05_21-07](https://huggingface.co/datasets/CabraVC/vector_dataset_stratified_ttv_split_2023-12-05_21-07) dataset that can be used for Text Classification. A [LogisticRegression](https://scikit-learn.org/stable/modules/generated/sklearn.linear_model.LogisticRegression.html) instance is used for classification. The model has been trained using an efficient few-shot learning technique that involves: 1. Fine-tuning a [Sentence Transformer](https://www.sbert.net) with contrastive learning. 2. Training a classification head with features from the fine-tuned Sentence Transformer. ## Model Details ### Model Description - **Model Type:** SetFit - **Classification head:** a [LogisticRegression](https://scikit-learn.org/stable/modules/generated/sklearn.linear_model.LogisticRegression.html) instance - **Maximum Sequence Length:** 512 tokens - **Number of Classes:** 3 classes - **Training Dataset:** [CabraVC/vector_dataset_stratified_ttv_split_2023-12-05_21-07](https://huggingface.co/datasets/CabraVC/vector_dataset_stratified_ttv_split_2023-12-05_21-07) ### Model Sources - **Repository:** [SetFit on GitHub](https://github.com/huggingface/setfit) - **Paper:** [Efficient Few-Shot Learning Without Prompts](https://arxiv.org/abs/2209.11055) - **Blogpost:** [SetFit: Efficient Few-Shot Learning Without Prompts](https://huggingface.co/blog/setfit) ### Model Labels | Label | Examples | |:------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | BUY | | | SELL | | | HOLD | | ## Evaluation ### Metrics | Label | Accuracy | |:--------|:---------| | **all** | 0.4583 | ## Uses ### Direct Use for Inference First install the SetFit library: ```bash pip install setfit ``` Then you can load this model and run inference. ```python from setfit import SetFitModel # Download from the 🤗 Hub model = SetFitModel.from_pretrained("setfit_model_id") # Run inference preds = model("year 2005, offset by a $663 million decline in Upgrade Advantage earned revenue. Information Worker operating income increased in fiscal year 2006 primarily due to the revenue growth, partially offset by a $283 million or 15% increase in sales and marketing expenses related to supporting field sales efforts and a $71 million or 10% increase in research and development expenses. Headcount-related costs increased 14% during fiscal year 2006 reflecting both an 18% increase in headcount related to supporting field sales efforts and research and development investments in future products and an increase in salaries and benefits for existing headcount, partially offset by a decrease in stock-based compensation expense. Information Worker operating income growth for fiscal year 2005 was primarily due to the revenue growth and a $304 million decrease in stock-based compensation expense. Operating expenses were also impacted by a reduction in marketing campaign costs from the previous period associated with the launch of Office 2003. This decline was offset by an increase in headcount-related costs as a result of an increase in headcount and an increase in salaries and benefits for existing headcount.   Microsoft Business Solutions   Microsoft Business Solutions provides business management software solutions targeted to businesses of varying sizes. The main products consist of enterprise resource planning (“ERP”) solutions, customer relationship management (“CRM”) software, retail solutions, Microsoft Partner Program (“MSPP”), and related services. Microsoft Business Solutions also includes the Small       and Mid-market Solutions and Partners (“SMS&P”), which focuses on sales to customers and partners in the small and mid-market customer segments. Revenue is derived from software and services sales, with software sales representing a significant amount of total revenue. Software revenues include both new software licenses and enhancement plans, which provide customers with future software upgrades over the period of the plan. Our solutions are delivered through a worldwide network of channel partners that provide services and local support. Microsoft Business Solutions revenue increased in fiscal year 2006 driven by new users for Microsoft CRM and existing Dynamics ERP customers purchasing functionality and user licenses. The increase in Microsoft Business Solutions revenue in fiscal year 2005 was mainly due to 10% revenue growth in software partially offset by 25% decline in services revenue. The software revenue increase was driven by 9% growth in license revenue and 16% growth in enhancement revenue and was attributed to growth in ERP and CRM solutions and an increase in MSPP subscriptions. Microsoft Business Solutions operating income increased in fiscal year 2006 reflecting the increase in revenue accompanied by a $56 million decrease in sales and marketing expense as a result of decreased net SMS&P spending. Headcount-related costs increased 3% reflecting both a 10% increase in headcount and an increase in salaries and benefits for existing headcount, partially offset by a decrease in stock-based compensation expense.") ``` ## Training Details ### Training Set Metrics | Training set | Min | Median | Max | |:-------------|:----|:---------|:----| | Word count | 431 | 479.2917 | 532 | | Label | Training Sample Count | |:------|:----------------------| | BUY | 3 | | HOLD | 6 | | SELL | 15 | ### Training Hyperparameters - batch_size: (6, 8) - num_epochs: (0, 32) - max_steps: -1 - sampling_strategy: oversampling - body_learning_rate: (0.0, 0.0) - head_learning_rate: 0.0002 - loss: CosineSimilarityLoss - distance_metric: cosine_distance - margin: 0.25 - end_to_end: False - use_amp: False - warmup_proportion: 0.1 - l2_weight: 0.08 - max_length: 512 - seed: 1003200212 - eval_max_steps: -1 - load_best_model_at_end: False ### Framework Versions - Python: 3.11.6 - SetFit: 1.0.1 - Sentence Transformers: 2.2.2 - Transformers: 4.35.2 - PyTorch: 2.1.1 - Datasets: 2.15.0 - Tokenizers: 0.15.0 ## Citation ### BibTeX ```bibtex @article{https://doi.org/10.48550/arxiv.2209.11055, doi = {10.48550/ARXIV.2209.11055}, url = {https://arxiv.org/abs/2209.11055}, author = {Tunstall, Lewis and Reimers, Nils and Jo, Unso Eun Seo and Bates, Luke and Korat, Daniel and Wasserblat, Moshe and Pereg, Oren}, keywords = {Computation and Language (cs.CL), FOS: Computer and information sciences, FOS: Computer and information sciences}, title = {Efficient Few-Shot Learning Without Prompts}, publisher = {arXiv}, year = {2022}, copyright = {Creative Commons Attribution 4.0 International} } ```